In vivo, BC treatment at 10 mg/kg suppressed tumor growth by 45% compared to the vehicle control, increased CD8+ T cell infiltration by 2.3-fold, and reduced immunosuppressive Tregs and myeloid-derived suppressor cells (MDSCs). The gene discussed is CD8A; the disease is neoplasm.